placebo + peginterferon alfa-2a

This is a combination of a placebo (an inert substance with no therapeutic effect) and peginterferon alfa-2a, a pegylated recombinant human interferon used primarily as an immunotherapy and antiviral agent. Peginterferon alfa-2a acts by binding to type 1 interferon receptors, activating the JAK/STAT pathway, and stimulating the innate antiviral response. It is indicated for chronic hepatitis B and C infections, certain myeloproliferative disorders (such as polycythaemia vera and essential thrombocythaemia), and has been studied in other conditions including melanoma. The addition of placebo in clinical trials serves as a control arm to assess the efficacy of peginterteron alfa-2a[1][2][3][4].